ProShare Advisors’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $313K | Sell |
36,992
-6,332
| -15% | -$60.3K | ﹤0.01% | 1313 |
|
|
2025
Q4 | $526K | Buy |
43,324
+13,089
| +43% | +$159K | ﹤0.01% | 1105 |
|
|
2025
Q3 | $353K | Sell |
30,235
-4,540
| -13% | -$54.3K | ﹤0.01% | 1317 |
|
|
2025
Q2 | $323K | Sell |
34,775
-6,543
| -16% | -$51.2K | ﹤0.01% | 1397 |
|
|
2025
Q1 | $303K | Sell |
41,318
-9,952
| -19% | -$76.5K | ﹤0.01% | 1406 |
|
|
2024
Q4 | $438K | Buy |
51,270
+12,669
| +33% | +$124K | ﹤0.01% | 1356 |
|
|
2024
Q3 | $336K | Buy |
38,601
+13,552
| +54% | +$112K | ﹤0.01% | 1388 |
|
|
2024
Q2 | $171K | Sell |
25,049
-3,449
| -12% | -$21.3K | ﹤0.01% | 1565 |
|
|
2024
Q1 | $259K | Buy |
28,498
+10,194
| +56% | +$72.3K | ﹤0.01% | 1524 |
|
|
2023
Q4 | $81.6K | Buy |
18,304
+2,985
| +19% | +$8.83K | ﹤0.01% | 1806 |
|
|
2023
Q3 | $48.1K | Buy |
15,319
+153
| +1% | +$626 | ﹤0.01% | 1719 |
|
|
2023
Q2 | $78.3K | Buy |
15,166
+758
| +5% | +$4.51K | ﹤0.01% | 1733 |
|
|
2023
Q1 | $75.9K | Sell |
14,408
-1,876
| -12% | -$8.91K | ﹤0.01% | 1630 |
|
|
2022
Q4 | $45.8K | Buy |
16,284
+1,298
| +9% | +$4.3K | ﹤0.01% | 1747 |
|
|
2022
Q3 | $62K | Buy |
14,986
+353
| +2% | +$1.78K | ﹤0.01% | 1637 |
|
|
2022
Q2 | $59K | Sell |
14,633
-7,683
| -34% | -$29K | ﹤0.01% | 1684 |
|
|
2022
Q1 | $111K | Sell |
22,316
-5,216
| -19% | -$28.9K | ﹤0.01% | 2009 |
|
|
2021
Q4 | $192K | Buy |
27,532
+1,347
| +5% | +$10.5K | ﹤0.01% | 2047 |
|
|
2021
Q3 | $262K | Sell |
26,185
-7,409
| -22% | -$83.2K | ﹤0.01% | 1641 |
|
|
2021
Q2 | $476K | Buy |
33,594
+3,709
| +12% | +$56.4K | ﹤0.01% | 1576 |
|
|
2021
Q1 | $490K | Buy |
29,885
+3,669
| +14% | +$70.7K | ﹤0.01% | 1454 |
|
|
2020
Q4 | $543K | Buy |
+26,216
| New | +$389K | ﹤0.01% | 1220 |
|
|
2019
Q4 | – | Sell |
-17,500
| Closed | -$53K | – | 1798 |
|
|
2019
Q3 | $53K | Buy |
17,500
+1,220
| +7% | +$5.45K | ﹤0.01% | 1597 |
|
|
2019
Q2 | $72K | Sell |
16,280
-1,609
| -9% | -$5.96K | ﹤0.01% | 1557 |
|
|
2019
Q1 | $71K | Buy |
17,889
+444
| +3% | +$1.78K | ﹤0.01% | 1596 |
|
|
2018
Q4 | $69K | Buy |
+17,445
| New | +$96.2K | ﹤0.01% | 1512 |
|
|
2016
Q4 | – | Sell |
-17,423
| Closed | -$120K | – | 1748 |
|
|
2016
Q3 | $120K | Sell |
17,423
-3,200
| -16% | -$19.5K | ﹤0.01% | 1404 |
|
|
2016
Q2 | $102K | Buy |
20,623
+614
| +3% | +$6.08K | ﹤0.01% | 1521 |
|
|
2016
Q1 | $193K | Sell |
20,009
-2,069
| -9% | -$15.7K | ﹤0.01% | 1432 |
|
|
2015
Q4 | $207K | Buy |
+22,078
| New | +$238K | ﹤0.01% | 1522 |
|
Other funds holding OCUL
DTC
ACA
SR
VA
VCM
ProShare Advisors's OCUL Position: Q1 2026 in Review
ProShare Advisors reduced its Ocular Therapeutix (OCUL) stake by 15% in Q1 2026, selling an estimated $60.3K and leaving 36,992 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #1313.
ProShare Advisors first reported a position in OCUL in Q4 2015 and has held it in 30 quarters since. The position peaked at $543K in Q4 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.
- ProShare Advisors held 36,992 shares of Ocular Therapeutix worth $313K as of Q1 2026.
- ProShare Advisors sold 6,332 Ocular Therapeutix shares in Q1 2026, an estimated $60.3K.
- Ocular Therapeutix made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1313 holding.
- ProShare Advisors first reported a position in Ocular Therapeutix in Q4 2015 and has held it in 30 quarters since.
- ProShare Advisors's Ocular Therapeutix position peaked at $543K in Q4 2020.
- 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.